Fjarde AP Fonden Fourth Swedish National Pension Fund Has $1.49 Million Stake in DaVita Inc. (NYSE:DVA)

Fjarde AP Fonden Fourth Swedish National Pension Fund decreased its holdings in shares of DaVita Inc. (NYSE:DVA) by 24.9% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 9,939 shares of the company’s stock after selling 3,300 shares during the quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund’s holdings in DaVita were worth $1,486,000 at the end of the most recent quarter.

Other institutional investors also recently modified their holdings of the company. FMR LLC lifted its stake in DaVita by 659.9% in the third quarter. FMR LLC now owns 177,406 shares of the company’s stock valued at $29,082,000 after buying an additional 154,061 shares in the last quarter. Glenmede Trust Co. NA lifted its position in shares of DaVita by 731.6% in the third quarter. Glenmede Trust Co. NA now owns 123,269 shares of the company’s stock worth $20,207,000 after purchasing an additional 108,446 shares in the last quarter. JPMorgan Chase & Co. lifted its position in shares of DaVita by 17.8% in the third quarter. JPMorgan Chase & Co. now owns 609,076 shares of the company’s stock worth $99,846,000 after purchasing an additional 92,014 shares in the last quarter. KBC Group NV increased its holdings in shares of DaVita by 27.3% in the third quarter. KBC Group NV now owns 313,519 shares of the company’s stock valued at $51,395,000 after purchasing an additional 67,250 shares during the last quarter. Finally, International Assets Investment Management LLC acquired a new position in shares of DaVita in the third quarter valued at $10,346,000. Institutional investors and hedge funds own 90.12% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have commented on DVA. Cowen reiterated a “hold” rating on shares of DaVita in a report on Tuesday, February 18th. Barclays upped their price objective on shares of DaVita from $164.00 to $169.00 and gave the stock an “equal weight” rating in a research report on Tuesday, February 18th. One investment analyst has rated the stock with a sell rating, four have given a hold rating and two have given a buy rating to the stock. According to MarketBeat.com, DaVita presently has an average rating of “Hold” and a consensus target price of $162.80.

DaVita Stock Performance

NYSE:DVA opened at $146.03 on Thursday. The company has a market capitalization of $11.68 billion, a PE ratio of 13.60, a P/E/G ratio of 1.07 and a beta of 0.93. The company has a 50 day simple moving average of $160.76 and a two-hundred day simple moving average of $158.13. The company has a debt-to-equity ratio of 23.18, a quick ratio of 1.21 and a current ratio of 1.26. DaVita Inc. has a fifty-two week low of $124.42 and a fifty-two week high of $179.60.

DaVita (NYSE:DVA) last released its earnings results on Thursday, February 13th. The company reported $2.24 earnings per share for the quarter, beating analysts’ consensus estimates of $2.14 by $0.10. DaVita had a net margin of 7.31% and a return on equity of 115.48%. Research analysts anticipate that DaVita Inc. will post 10.76 earnings per share for the current year.

DaVita Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.